Abstract
AbstractSalivary gland cancers (SGCs) are rare yet aggressive malignancies with significant histological heterogeneity, which has made prediction of prognosis and development of targeted therapies challenging. In majority of patients, local recurrence and/or distant metastasis are common and systemic treatments have minimal impact on survival. Therefore, identification of novel targets for treatment that can also be used as predictors of recurrence for multiple histological subtypes of SGCs is an area of unmet need. In this study, we developed a novel transgenic mouse model of SGC, efficiently recapitulating the major histological subtype (adenocarcinomas of the parotid gland) of human SGC. CDK2 knock out (KO) mice crossed with MMTV-low molecular weight forms of cyclin E (LMW-E) mice generated the transgenic mouse models of SGC, which arise in the parotid region of the salivary gland, similar to the common site of origin seen in human SGCs. To identify the CDK2 independent catalytic partner(s) of LMW-E, we used LMW-E expressing cell lines in mass spectrometric analysis and subsequent biochemical validation in pull down assays. These studies revealed that in the absence of CDK2, LMW-E preferentially binds to CDK5. Molecular targeting of CDK5, using siRNA, resulted in inhibition of cell proliferation of human SGCs overexpressing LMW-E. We also provide clinical evidence of significant association of LMW-E/CDK5 co-expression and decreased recurrence free survival in human SGC. Immunohistochemical analysis of LMW-E and CDK5 in 424 patients representing each of the four major histological subtypes of human salivary cancers (Aci, AdCC, MEC, and SDC) revealed that LMW-E and CDK5 are concordantly (positive/positive or negative/negative) expressed in 70% of these patients. The co-expression of LMW-E/CDK5 (both positive) robustly predicts the likelihood of recurrence, regardless of the histological classification of these tumors. Collectively, our results suggest that CDK5 is a novel and targetable biomarker for the treatment of patients with SGC presenting with LMW-E overexpressing tumors.
Funder
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Cancer Prevention and Research Institute of Texas
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Molecular Biology
Reference38 articles.
1. Noone A. M. et al. (eds). SEER Cancer Statistics Review. (National Cancer Institute Bethesda, MD, 1975–2015).
2. Son, E., Panwar, A., Mosher, C. H. & Lydiatt, D. Cancers of the major salivary gland. J. Oncol. Pract. 14, 99–108 (2018).
3. El-Naggar A. K., C J., Grandis J. R., Takata T., Slootweg P. J., (eds). Tumours of salivary glands. in WHO classification of head and neck tumours. 4th ed. (International Agency for Research on Cancer, Lyon, 2017). p. 159–202.
4. Coca-Pelaz, A. et al. Adenoid cystic carcinoma of the head and neck—an update. Oral. Oncol. 51, 652–661 (2015).
5. Patel, N. R. et al. Demographic trends and disease-specific survival in salivary acinic cell carcinoma: an analysis of 1129 cases. Laryngoscope 124, 172–178 (2014).
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献